Twice-yearly access, launch readiness, and coverage support
YEZTUGO is given as two subcutaneous injections every 6 months after starter dosing. On day 1, the patient receives two oral tablets and two injections in a medical setting. On day 2, two more oral tablets are taken at home. HIV testing is required before starting and before each injection visit.
Launch readiness for YEZTUGO means more than writing a page or placing the drug on a list. Sites need procurement and specialty-pharmacy routing, staff training on subcutaneous administration, storage and handling workflow, scheduling logic for six-month follow-up, HIV testing workflow, billing setup, and a clear plan for delayed injections.
Gilead Advancing Access can help with benefits investigations, prior authorization, co-pay program enrollment for eligible commercially insured patients, and medication-assistance pathways. The program can be reached at 1-800-226-2056.